ollowing two years of virtual meetings, the opportunity to gather in person for the 11th International Congress of Arthroplasty Registries, hosted by the Irish National Orthopaedic Register (INOR) in Dublin early September 2022, was truly delightful. Selected proceedings from this congress in this issue of CORR ® highlight the diverse range of topics addressed by the International Society of Arthroplasty Registries (ISAR) and its member registries, demonstrating a comprehensive approach to improving arthroplasty care. Arthroplasty registries extend beyond monitoring prosthesis performance and implant survival; they explore various factors such as patient characteristics, surgical techniques, hospital and surgeon performance, and care processes [7]. Many registries also capture additional endpoints of interest like patient-reported measures, readmissions, and nonrevision-related adverse events either directly or through data linkage [1,14] .One of the keynote speakers at the meeting was cardiologist Alan Fraser, who leads a project funded by the European Union Horizon 2020 called Coordinating Research and Evidence for Medical Devices (CORE-MD) [2]. This collaborative project, encompassing care for patients with cardiac conditions, diabetes, and musculoskeletal problems, aims to enhance clinical investigation methods and evaluation of high-risk medical devices. The introduction of the Medical Device Regulation (EU) 2017/745-which created more stringent standards for monitoring and reporting the performance of medical devices-has changed the landscape and increased the need for engagement between the medical community, regulators, notified bodies, and implant manufacturers. In this context, registries play a critical role by providing stakeholders with relevant information for such evaluations.Within these CORR proceedings, two studies demonstrate how registry data can be utilized to assess implant performance. It has been observed that certain variants or constructs within an otherwise well-performing implant